Immunotherapy of MHC class I-deficient tumors

0352661 - ÚMG 2011 RIV GB eng J - Journal Article
Reiniš, Milan
Immunotherapy of MHC class I-deficient tumors.
Future Oncology. Roč. 6, č. 10 (2010), s. 1577-1589. ISSN 1479-6694. E-ISSN 1744-8301
R&D Projects: GA ČR GA301/07/1410; GA ČR GAP301/10/2174; GA AV ČR IAA500520807; GA AV ČR IAA500520605
EU Projects: European Commission(XE) 18933 - CLINIGENE
Institutional research plan: CEZ:AV0Z50520514
Keywords : tumor vaccine * MHC class I expression * antigen presenting machinery
Subject RIV: EB - Genetics ; Molecular Biology
Impact factor: 2.455, year: 2010

MHC class I downregulation is a general mechanism by which tumor cells can escape from T-cell-mediated immunity. Therefore, successful imunotherapeutic and vaccination protocols should be optimized against tumors with distinct cell surface expression of the MHC class I molecules. Mechanisms leading to protective immunity may vary in different models with respect to the particular tumors, e.g. to their levels of residual expression of the MHC class I molecules on tumor cells or inducibility of MHC class I expression. Notably, both CD8+ cell-mediated immunity and MHC class I-unrestricted mechanisms can take place against MHC class I-deficient tumors. Since MHC class I downregulation is frequently reversible by cytokines and also by activation of epigenetically silenced genes, an attractive strategy is to elicit specific cell-mediated immunity combined with restoration of MHC class I expression on tumor cells.
Permanent Link: http://hdl.handle.net/11104/0192124